Latest From Biotech Now

Europe Turns its Back on Science

Mark Lynas

On October 24th, The New York Times published a great opinion piece titled “With G.M.O. Policies, Europe Turns Against Science. Written by Mark Lynas, political director for the Cornell Alliance for Science at Cornell University and a co-author  of “An Ecomodernist Manifesto,” this piece argues how banning the cultivation of genetically modified crops in certain European countries will a chilling affect on scientific innovation in that part of the world.   “…the chilling effect on biotech science in Europe will be dramatic: Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Setting the Record Straight on Innovation and Drug Development

stethoscope

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases. That’s why it is important that policy proposals designed to respond to the activities of outliers like Turing Pharmaceuticals and Valeant do not hurt America’s leadership in biotechnology innovation and investment. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Mesothelioma: Once Hopeless Cancer, on the Verge of Promising Advances

MesoAwarenessCarouselGraphic

Mesothelioma, the word, (pronounced mez-uh-thee-lee-oh-muh) is often much better known than the illness it represents. The legal issues surrounding this cancer make mesothelioma, the most expensive keyword on Google (while most keywords cost pennies, the keyword mesothelioma can cost over $300 per click). Mesothelioma, the illness, is a cancer that most often affects the lining of the lung or abdomen; it has no cure and treatment options for patients are few. Prognosis is generally considered Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Haves and Have Nots in Biotech Venture Capital

US_VC_Funding_2009_2014

Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” in US biopharma venture capital. Three key findings were discussed Wednesday at the 14th Annual BIO Investor Forum. The first finding from the recent study is that funding of therapeutic companies is strong for late rounds (Series B and above), but weak for Series A. Although total levels of venture funding have been climbing recently, the majority of the increase is from late rounds. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

“Get to Know” More About Land, Soil and GMOs

GMO Answers

Throughout this month we’ve invited you to get to know more about GMOs, how the technology has evolved, to sustainable agricultural practices to the balancing act between producing food and protecting pollinators. In week four, we’re focusing on “Land, Soil, Sustainability.” The availability of farmland is essential to agricultural production. Land use and soil health play a critical role in sustainable agriculture…In order for land to be used for agriculture, it must first be suitable Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,